ICI 204,636, an atypical antipsychotic: Efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia

Journal of Clinical Psychopharmacology

Volumn 16, Issue 2, 1996, Pages 158-169

  Borison, Richard L ^a   Arvanitis, Lisa A ^b   Miller, Barbara G ^b  

^a Psychiatry Service   (United States)

^b Zeneca Pharmaceutical   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT; PLACEBO; QUETIAPINE;

ADULT; AGITATION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERANCE; FEMALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE;

ACUTE DISEASE; ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; DIBENZOTHIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 0029878084     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199604000-00008     Document Type: Article

References (22)

1. Kane J, Honigfeld G, Singer J, Meltzer H, the Clozaril Collaborative Study Group. Clozapine for the treatment-resistant schizophrenic, a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-96.
2. Breier A, Buchanan RW, Kirkpatrick B, Davis OR, Irish D, Summerfelt A, Carpenter WT, Jr. Effects of clozapine on positive, negative symptoms in outpatients with schizophrenia. Am J Psychiatry 1994;151:20-6.
3. Pickar D, Owen RR, Litman RE, Konicki E, Gutierrez R, Rapaport MH. Clinical and biologic response to clozapine in patients with schizophrenia: crossover comparison with fluphenazine. Arch Gen Psychiatry 1992;49:345-53.
4. Meltzer HY, Bernett S, Bastani B, Ramirez LF. Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp Community Psychiatry 1990;41:892-7.
5. Griffith RW, Saameli K. Clozapine and agranulocytosis. Lancet 1975;2:657.
6. Idänpään-Heikkilä J, Alhava E, Olkinuora M, Palva IP. Agranulocytosis during treatment with clozapine. Eur J Clin Pharmacol 1977;11:193-8.
7. Grohmann R, Rüther E, Sassim N, Schmidt LG. Adverse effects of clozapine. Psychopharmacology 1989;99:S101-4.
8. Chakrabarti JK, Hotten TM, Pullar IA, Tye NC. Synthesis and pharmacological evaluation of a series of 4-piperazinylpyrazolo[3,4-b]- and -[4,3-b][1,5]benzodiazepines as potential anxiolytics. J Med Chem 1989;32:2573-82.
9. Hunziker F, Fischer R, Kipfer P, Schumltz J, Bürki HR, Eichenberger E, White TG. Neuroleptic piperazinyl derivatives of 10H-thieno [3,2-c] [1] benzazepines and 4H-thieno [2,3-c] [1] benzazepines. Eur J Med Chem 1981;16:391-8.
10. Davis DA, de Paulis T, Janowsky A, Smith HE, Chloro-substituted, sterically hindered 5,11-dicarbo analogues of clozapine as potential chiral antipsychotIc agents. J Med Chem 1990;33:809-14.
11. Saller CF, Salama AI. Seroquel: biochemical profile of a potential atypical antiopsychotic. Psychopharmacology 1993;112:285-92.
12. Goldstein JM. Pre-clinical pharmacology of new atypical antipsychotics in late stage development. Expert Opinion Invest Drugs 1995;4:291-8.
13. Goldstein JM, Litwin LC, Sutton EB, Malick JB, Seroquel: electrophysiological profile of a potential atypical antipsychotic. Psychopharmacology 1993;112:293-8.
14. Migler BM, Warawa EJ, Malick JB. Seroquel: behavioral effects in conventional and novel tests for atypical antipsychotic drug. Psychopharmacology 1993;112:299-307.
15. Goldstein JM, Snyder DH. Effects of Seroquel, clozapine, and other putative atypical antipsychotic agents in primate models of dystonia. Schizophr Res 1995;15:152.
16. Fabre L, Slotnick V, Jones V, Murray G, Malick J, ICI 204,636, a novel atypical antipsychotic: early indication for safety and efficacy in man (abstract). 17th Congress of Collegium Internationale Neuro-Psychopharmacologicum, Kyoto, Japan, September 10-14, 1990; 0-13-3-8:223.
17. Fabre LF Jr. A multicenter, open, pilot trial of ICI 204,636 in hospitalized patients with acute psychotic symptomatology (abstract). Schizophr Res 1993:2-3:237.
18. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970;45[suppl 212]:11-9.
19. Andreasen N. Modified scale for the assessment of negative symptoms. Department of Health and Human Services, Public Health Administration. NIMH treatment strategies in schizophrenia study. Washington, DC, 1984;ADM 9-102.
20. Guy W, ed. ECDEU assessment manual for psychopharmacology (revised edition). Rockville, MD: U.S. Department of Health and Human Services (ADM 76-338), 1976:534-5.
21. Goldstein JM, Arvanitis LA. ICI 204,636 (Seroquel): A dibenzothiazepine atypical antipsychotic. Review of preclinical pharmacology and highlights of Phase II clinical trials. CNS Drug Rev 1995; 1:50-73.
22. Cohen S, Chiles J, MacNaughton A. Weight gain associated with clozapine. Am J Psychiatry 1990;147:503-4.